Peptides and Chronic Pain: What Research Shows About Central Sensitisation and Why Persistent Pain Is Not Just Tissue Damage

Persistent pain often outlasts the injury that started it, driven by changes in how the nervous system processes signals. This article reviews what preclinical research suggests about peptides, inflammation and pain signalling, and why clinical screening comes first.

By UAE Peptide Clinic Research Desk

Acute pain is a useful alarm: tissue is damaged, nociceptors fire, and the signal fades as the tissue heals. Chronic pain, usually defined as pain persisting beyond three months, often follows a different logic. In many people the original injury has healed on imaging, yet the pain continues. Understanding why is central to any sensible conversation about peptides, because it determines which kinds of research are relevant and which are not.

What central sensitisation means

Central sensitisation describes a state in which neurons in the spinal cord and brain become more responsive to incoming signals. Stimuli that would normally feel mild may be perceived as painful (allodynia), and painful stimuli may feel amplified (hyperalgesia). It is thought to contribute to conditions such as fibromyalgia, chronic low back pain and some persistent post-surgical pain, although the extent varies considerably between individuals.

Several mechanisms are implicated. Repeated nociceptive input can lower the firing threshold of dorsal horn neurons. Glial cells in the spinal cord can release inflammatory mediators that sustain that heightened state. Descending pathways from the brainstem, which normally dampen pain signals, can become less effective, particularly when sleep is poor or stress is chronically elevated.

Persistent pain is frequently a problem of signal processing as much as tissue damage, which is why a single repair-focused approach rarely explains the whole picture.

Where peptide research is relevant

The body uses peptides extensively in pain regulation. Endogenous opioid peptides such as the enkephalins and endorphins modulate pain transmission, and neuropeptides such as substance P and calcitonin gene-related peptide (CGRP) promote it. This makes the peptide field a natural area of investigation, but it is important to separate endogenous biology from the evidence for any specific therapeutic peptide.

In short, much of the available data are preclinical, drawn from animal models, and cannot be assumed to translate to people with chronic pain. Research suggests plausible mechanisms; it does not establish that any peptide treats central sensitisation.

The role of sleep, stress and recovery

Sleep restriction lowers pain thresholds in controlled studies, and persistent pain in turn fragments sleep, creating a loop. Slow-wave sleep is also when the main pulse of growth hormone is released. For this reason, clinicians often look at sleep quality, cortisol patterns and training load before considering any peptide, because correcting these upstream factors may matter more than any single compound.

Clinical nuance: pain needs a diagnosis first

New, worsening or unexplained pain should be properly assessed before it is attributed to sensitisation. Red flags such as unexplained weight loss, night pain, neurological deficits, fever or a history of malignancy need conventional investigation. Medications such as gabapentinoids, opioids, antidepressants and anti-inflammatories also interact with protocol planning, and should always be disclosed to the prescribing physician.

Non-drug approaches such as graded exercise, physiotherapy, pain education and cognitive behavioural therapy have the strongest evidence base for chronic pain and remain first-line. Peptide protocols, where appropriate, are considered an adjunct under physician oversight rather than a replacement.

If you're exploring chronic pain or recovery as part of your protocol, our clinical team can review your case — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.